BioSpark AI Technologies Inc.
BioSpark AI Technologies Inc. is a rapidly growing start-up on a mission to turn the patient data industry upside-down. We are the first company to systematically capture patient journeys and drug-related adverse event causality using state-of-the-art AI applied to peer reviewed case reports. Our database and platform, OpenCase (TM), houses patient data from over 125 countries worldwide, including over 15,000 hematological cancer patient data and over 20,000 patient data across a number of solid tumors.